Dendritic cell vaccines in the treatment of multiple myeloma: advances and limitations
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2002-01-01 / Med. Oncol. 2002;19(4):213-8The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2002-01-01 / Int J Gastrointest Cancer 2002;32(1):1-6Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression
/in Dendritic Cells, International Publications, Soft Tissue Sarcoma /von 2001-12-01 / Cancer Res. 2001 Dec;61(23):8513-9Heat shock and heat shock protein 70i enhance the oncolytic effect of replicative adenovirus
/in Hyperthermia, International Publications, Newcastle Disease Virus /von 2001-12-01 / Cancer Res. 2001 Dec;61(23):8361-5Effective treatment of small murine hepatocellular carcinoma by dendritic cells
/in Hepatocellular Carcinoma, International Publications /von 2001-11-01 / Hepatology 2001 Nov;34(5):896-905Dendritic cells in cancer vaccines
/in International Publications, Ovarian Cancer /von 2001-11-01 / Exp. Hematol. 2001 Nov;29(11):1247-55Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration
/in International Publications, Newcastle Disease Virus /von 2001-10-22 / Cancer Lett. 2001 Oct;172(1):27-36Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination
/in Dendritic Cells, International Publications, Thyroid Cancer /von 2001-10-01 / J. Clin. Endocrinol. Metab. 2001 Oct;86(10):4965-9Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells
/in Dendritic Cells, Glioblastoma, International Publications /von 2001-09-01 / Cancer Immunol. Immunother. 2001 Sep;50(7):337-44
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution